Analysis of Unusual Adverse Effects After Radium-223 Dichloride Administration

(E-pub Ahead of Print)

Author(s): Viviana Frantellizzi*, Mariano Pontico, Arianna Pani, Roberto Pani, Giuseppe De Vincentis.

Journal Name: Current Radiopharmaceuticals

Become EABM
Become Reviewer

Abstract:

Background: To our knowledge, no previous study or literature review has been performed about the effects of the extravasation of therapeutic radiopharmaceutical agents and its potential consequences, especially regarding alpha-particle emitting radiopharmaceuticals.

Methods: Even if Radium-223 dichloride is known to be a relatively safe drug to manage, despite the correctness of the procedures applied , unexpected delayed adverse effects can occur.

In our vast experience, we rarely observed lymphedema ,even after some time, at the site of administration.

Results: Management of lymphedema caused by radiopharmaceuticals administration has been addressed through clinical examples. The sudden intervention allowed a fast remission of the signs and symptoms complained by patients treated with Radium-223 dichloride.

Conclusions: The management of adverse effects after radiopharmaceuticals administration as in case of lymphedema onset, is extremely simple. These data confirms the safety of Radium-223 treatment.

Keywords: Ra-223 dichloride, alpha particle therapy, lymphedema, life quality, radiopharmaceutical adverse effects

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1874471012666190927115331

Article Metrics

PDF: 9